Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 20 studies | 35% ± 15% | |
astrocyte | 16 studies | 41% ± 21% | |
B cell | 14 studies | 30% ± 17% | |
oligodendrocyte | 13 studies | 53% ± 16% | |
microglial cell | 13 studies | 49% ± 15% | |
oligodendrocyte precursor cell | 12 studies | 45% ± 18% | |
glutamatergic neuron | 10 studies | 56% ± 24% | |
macrophage | 10 studies | 43% ± 18% | |
GABAergic neuron | 9 studies | 53% ± 27% | |
naive B cell | 9 studies | 21% ± 3% | |
fibroblast | 9 studies | 35% ± 10% | |
CD16-positive, CD56-dim natural killer cell, human | 8 studies | 21% ± 9% | |
adipocyte | 8 studies | 37% ± 11% | |
mast cell | 8 studies | 33% ± 8% | |
CD16-negative, CD56-bright natural killer cell, human | 7 studies | 23% ± 9% | |
natural killer cell | 7 studies | 28% ± 12% | |
CD4-positive, alpha-beta T cell | 6 studies | 25% ± 9% | |
interneuron | 6 studies | 54% ± 29% | |
mucosal invariant T cell | 6 studies | 23% ± 9% | |
epithelial cell | 6 studies | 36% ± 25% | |
dendritic cell | 6 studies | 36% ± 14% | |
T cell | 6 studies | 34% ± 13% | |
endothelial cell of lymphatic vessel | 6 studies | 38% ± 11% | |
pericyte | 6 studies | 27% ± 12% | |
smooth muscle cell | 6 studies | 26% ± 5% | |
effector memory CD8-positive, alpha-beta T cell | 5 studies | 24% ± 10% | |
memory B cell | 5 studies | 16% ± 1% | |
retinal cone cell | 5 studies | 62% ± 26% | |
myeloid cell | 5 studies | 36% ± 10% | |
monocyte | 5 studies | 45% ± 11% | |
non-classical monocyte | 4 studies | 22% ± 3% | |
granule cell | 4 studies | 56% ± 17% | |
neuron | 4 studies | 52% ± 23% | |
precursor B cell | 4 studies | 18% ± 1% | |
plasma cell | 4 studies | 36% ± 14% | |
CD8-positive, alpha-beta T cell | 4 studies | 26% ± 10% | |
cardiac muscle cell | 4 studies | 32% ± 8% | |
Mueller cell | 4 studies | 35% ± 16% | |
amacrine cell | 4 studies | 40% ± 24% | |
retina horizontal cell | 4 studies | 31% ± 18% | |
retinal ganglion cell | 4 studies | 53% ± 27% | |
retinal rod cell | 4 studies | 55% ± 15% | |
type I pneumocyte | 4 studies | 40% ± 9% | |
type II pneumocyte | 4 studies | 40% ± 10% | |
CD8-positive, alpha-beta memory T cell | 4 studies | 19% ± 3% | |
regulatory T cell | 4 studies | 26% ± 8% | |
GABAergic interneuron | 3 studies | 42% ± 7% | |
immature B cell | 3 studies | 19% ± 2% | |
mesothelial cell | 3 studies | 35% ± 8% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 29% ± 10% | |
vein endothelial cell | 3 studies | 33% ± 22% | |
GABAergic amacrine cell | 3 studies | 40% ± 20% | |
OFF-bipolar cell | 3 studies | 40% ± 20% | |
ON-bipolar cell | 3 studies | 49% ± 20% | |
glycinergic amacrine cell | 3 studies | 41% ± 16% | |
hepatocyte | 3 studies | 64% ± 30% | |
mature NK T cell | 3 studies | 27% ± 15% | |
retinal pigment epithelial cell | 3 studies | 56% ± 22% | |
ependymal cell | 3 studies | 37% ± 20% | |
capillary endothelial cell | 3 studies | 25% ± 6% | |
ciliated cell | 3 studies | 32% ± 13% | |
club cell | 3 studies | 36% ± 13% | |
respiratory goblet cell | 3 studies | 43% ± 15% | |
gamma-delta T cell | 3 studies | 18% ± 1% | |
lymphocyte | 3 studies | 53% ± 15% | |
basal cell | 3 studies | 45% ± 31% | |
leukocyte | 3 studies | 56% ± 10% | |
mural cell | 3 studies | 39% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2033.65 | 1445 / 1445 | 100% | 9.65 | 183 / 183 |
stomach | 100% | 2208.56 | 359 / 359 | 100% | 10.46 | 286 / 286 |
intestine | 100% | 2508.67 | 966 / 966 | 100% | 10.89 | 526 / 527 |
lung | 100% | 2096.10 | 578 / 578 | 100% | 8.34 | 1152 / 1155 |
prostate | 100% | 1904.37 | 245 / 245 | 100% | 9.62 | 500 / 502 |
breast | 100% | 2216.24 | 459 / 459 | 99% | 10.34 | 1112 / 1118 |
pancreas | 100% | 1804.92 | 328 / 328 | 99% | 8.74 | 177 / 178 |
thymus | 100% | 2636.89 | 653 / 653 | 99% | 12.55 | 600 / 605 |
bladder | 100% | 2154.19 | 21 / 21 | 99% | 8.56 | 498 / 504 |
brain | 99% | 2420.27 | 2617 / 2642 | 99% | 6.89 | 700 / 705 |
uterus | 100% | 2185.68 | 170 / 170 | 98% | 9.10 | 450 / 459 |
kidney | 100% | 1476.18 | 89 / 89 | 98% | 8.68 | 879 / 901 |
ovary | 100% | 1990.64 | 180 / 180 | 97% | 6.33 | 415 / 430 |
adrenal gland | 100% | 1914.28 | 258 / 258 | 95% | 6.64 | 219 / 230 |
skin | 100% | 2619.89 | 1809 / 1809 | 94% | 6.51 | 446 / 472 |
liver | 100% | 1077.57 | 226 / 226 | 88% | 4.59 | 356 / 406 |
adipose | 100% | 2026.39 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 12.06 | 29 / 29 |
spleen | 100% | 2477.01 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 9.85 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.07 | 1 / 1 |
blood vessel | 100% | 2215.43 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 1024.54 | 797 / 803 | 0% | 0 | 0 / 0 |
heart | 95% | 1053.16 | 818 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 1786.97 | 879 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 78% | 3.88 | 62 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0010468 | Biological process | regulation of gene expression |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_2000736 | Biological process | regulation of stem cell differentiation |
GO_0006338 | Biological process | chromatin remodeling |
GO_0019827 | Biological process | stem cell population maintenance |
GO_0060765 | Biological process | regulation of androgen receptor signaling pathway |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0030521 | Biological process | androgen receptor signaling pathway |
GO_0001825 | Biological process | blastocyst formation |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005721 | Cellular component | pericentric heterochromatin |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0032454 | Molecular function | histone H3K9 demethylase activity |
GO_0062072 | Molecular function | H3K9me3 modified histone binding |
GO_0032452 | Molecular function | histone demethylase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0050681 | Molecular function | nuclear androgen receptor binding |
GO_0140684 | Molecular function | histone H3K9me2/H3K9me3 demethylase activity |
GO_0030374 | Molecular function | nuclear receptor coactivator activity |
GO_0051864 | Molecular function | histone H3K36 demethylase activity |
Gene name | KDM4C |
Protein name | Lysine demethylase 4C Lysine-specific demethylase 4C (EC 1.14.11.66) (Gene amplified in squamous cell carcinoma 1 protein) (GASC-1 protein) (JmjC domain-containing histone demethylation protein 3C) (Jumonji domain-containing protein 2C) ([histone H3]-trimethyl-L-lysine(9) demethylase 4C) |
Synonyms | GASC1 JMJD2C JHDM3C KIAA0780 |
Description | FUNCTION: Histone demethylase that specifically demethylates 'Lys-9' and 'Lys-36' residues of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27' nor H4 'Lys-20'. Demethylates trimethylated H3 'Lys-9' and H3 'Lys-36' residue, while it has no activity on mono- and dimethylated residues. Demethylation of Lys residue generates formaldehyde and succinate. . |
Accessions | ENST00000381309.8 [Q9H3R0-1] B0QZ60 A0A0A0MSR6 ENST00000420847.2 ENST00000543771.5 [Q9H3R0-3] ENST00000381306.7 [Q9H3R0-2] ENST00000428870.6 F8WCN1 C9J879 ENST00000438023.5 Q9H3R0 ENST00000536108.5 [Q9H3R0-4] ENST00000401787.7 |